Levossimendano Waymade

Active Ingredient:: Levosimendan
Origin:: EU

Levossimendano Waymade (Levosimendan)

Q: What is Levossimendano Waymade used for?

Levossimendano Waymade contains levosimendan, which is indicated for the treatment of acute decompensated heart failure in adult patients. It helps improve cardiac output and relieve symptoms associated with sudden worsening of heart function.

Q: How does levosimendan work?

Levosimendan sensitises cardiac troponin C to calcium, enhancing contractile force without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces both preload and afterload, thereby supporting overall cardiac performance.

Q: What is the usual dose of Levossimendano Waymade?

The dosage of Levossimendano Waymade is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber will set the appropriate infusion rate and duration according to current medical guidelines.

Q: Is Levossimendano Waymade safe in pregnancy or breastfeeding?

Safety data for levosimendan during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and under strict medical supervision.

Q: How do I order Levossimendano Waymade from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Q: How does levosimendan compare with other inotropes?

Unlike traditional catecholamine inotropes, levosimendan increases contractility by calcium sensitisation rather than raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that some clinicians prefer in specific heart‑failure scenarios.

Q: What are the storage and handling requirements for Levossimendano Waymade?

Levossimendano Waymade should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze. Inspect the solution for particulate matter before use and discard if any are observed.

Q: How is Levossimendano Waymade administered?

The product is supplied as an intravenous solution and is administered by controlled infusion through a dedicated IV line. Administration is performed by qualified healthcare professionals in a hospital or clinical setting, following aseptic technique and monitoring protocols.

Q: What are the most serious risks associated with levosimendan?

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactic reactions. Patients should be closely monitored for blood‑pressure changes, ECG abnormalities, and signs of allergic response throughout the infusion period.

Q: Who should not receive Levossimendano Waymade?

Levossimendano Waymade is contraindicated in patients with severe hypotension (systolic blood pressure <90 mmHg), known hypersensitivity to levosimendan or any excipients, and in those receiving other calcium‑sensitising agents. Caution is also advised for patients with significant hepatic impairment.

Levosimendan, the active ingredient in Levossimendano Waymade, is a calcium sensitizer / inodilator presented as an intravenous solution for intravenous use. It treats acute decompensated heart failure in adult patients.

GNH India supplies Levossimendano Waymade as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres and specialty pharmacies worldwide under strict quality‑assurance protocols. The company ensures cold‑chain logistics where required and complies with EU marketing authorisation standards. Clients receive comprehensive documentation, batch release certificates and regulatory support for importation into diverse markets.

Manufacturer / TM Owner

Waymade Plc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in the management of acute decompensated heart failure, a condition characterised by sudden worsening of cardiac function.
Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion.
Low cardiac output syndrome: increases stroke volume and enhances organ perfusion.
Cardiogenic shock (off‑label): provides inotropic support when conventional agents are insufficient.
Chronic heart failure (off‑label): may improve symptoms and exercise tolerance in selected patients.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractility without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing both preload and afterload, which together improve cardiac output in heart‑failure states.

Side Effects

Levosimendan may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

Hypotension: transient drop in blood pressure, often dose‑related.
Headache: mild to moderate intensity, usually resolves spontaneously.
Nausea: occasional, may be accompanied by mild vomiting.
Tachycardia: increased heart rate, generally self‑limiting.

Serious or Rare Side Effects

Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
Severe hypotension: profound blood‑pressure fall requiring intervention.
Anaphylactic reactions: rare but may include rash, bronchospasm, and shock.
Liver enzyme elevation: transient increase in transaminases.
Pulmonary edema: fluid accumulation in lungs, especially in patients with pre‑existing congestion.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures before and during therapy.
Monitor blood pressure: watch for hypotension, especially after loading dose.
Observe cardiac rhythm: continuous ECG monitoring for arrhythmias.
Adjust dose in renal impairment: reduce infusion rate in patients with severe renal dysfunction.
Avoid use in severe hypotension: contraindicated when systolic pressure is <90 mmHg.
Use cautiously with other vasodilators: risk of additive blood‑pressure lowering.
Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Levosimendan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.
Concurrent use with other calcium sensitizers: risk of excessive inotropy.
Nitrates or other potent vasodilators: may cause severe hypotension.

Moderate Interactions (Monitor Closely)

Diuretics: may potentiate electrolyte disturbances and hypotension.
Beta‑blockers: may blunt desired inotropic effect.
ACE inhibitors or ARBs: combined effect on blood pressure requires monitoring.

Frequently Asked Questions

Levossimendano Waymade contains levosimendan, which is indicated for the treatment of acute decompensated heart failure in adult patients. It helps improve cardiac output and relieve symptoms associated with sudden worsening of heart function.

Levosimendan sensitises cardiac troponin C to calcium, enhancing contractile force without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that reduces both preload and afterload, thereby supporting overall cardiac performance.

The dosage of Levossimendano Waymade is determined by the prescribing clinician based on the patient’s clinical condition, weight, and response. The prescriber will set the appropriate infusion rate and duration according to current medical guidelines.

Safety data for levosimendan during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and under strict medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan increases contractility by calcium sensitisation rather than raising intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that some clinicians prefer in specific heart‑failure scenarios.

Levossimendano Waymade should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze. Inspect the solution for particulate matter before use and discard if any are observed.

The product is supplied as an intravenous solution and is administered by controlled infusion through a dedicated IV line. Administration is performed by qualified healthcare professionals in a hospital or clinical setting, following aseptic technique and monitoring protocols.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare anaphylactic reactions. Patients should be closely monitored for blood‑pressure changes, ECG abnormalities, and signs of allergic response throughout the infusion period.

Levossimendano Waymade is contraindicated in patients with severe hypotension (systolic blood pressure <90 mmHg), known hypersensitivity to levosimendan or any excipients, and in those receiving other calcium‑sensitising agents. Caution is also advised for patients with significant hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.